A noninvasive DNA blood test can identify metastatic castration-resistant prostate cancer (mCRPC) patients who are most ...

SAN FRANCISCO -- Circulating tumor DNA (ctDNA) measurements showed promise for identifying patients with early colorectal ...

New data from two large studies presented at the 2025 ASCO Gastrointestinal Cancers Symposium (GICS) 2025 provide evidence of the clinical utility of circulating tumor DNA (ctDNA) testing in ...

Marks third NCCN guideline recommendation on ctDNA-MRD testing, following positive guideline changes in merkel cell carcinoma and diffuse large b-cell lymphoma AUSTIN, Texas--(BUSINESS WIRE)--Natera, ...

Serial circulating tumor DNA (ctDNA) testing showed limited clinical benefit in colorectal cancer (CRC) surveillance when frequent imaging is used. The study's retrospective design and small sample ...

Earlier blood-test detection could help identify pancreatic cancer patients who need more aggressive treatment, an expert told Newsweek.

Please provide your email address to receive an email when new articles are posted on . Approximately 25% of patients had ctDNA- or imaging-confirmed recurrence. More than 30% had evidence of ...

Dr. Alan Tan explores circulating tumor DNA, its role in clinical trials and its potential impact on patients with renal cell carcinoma. Circulating tumor DNA (ctDNA) is not yet standard practice in ...

A highly sensitive blood test can detect signs of pancreatic cancer that standard methods often miss, according to results of ...

Dr. W. Fraser Symmans explains how ctDNA is replacing CTCs to monitor breast cancer, detect mutations and track minimal residual disease At the CURE Educated Patient Breast Cancer Summit, held during ...